



HAWAII DEPARTMENT OF HEALTH

# COVID-19 Vaccine Information

Thursday, December 10



# Governor David Ige

---



# Lieutenant Governor Josh Green

---



# Pfizer/BioNTech BNT162b2 Vaccine

- mRNA COVID-19 vaccine
- 2 dose injection, 21 days apart
- Phase 3 clinical trial began July 27, 2020
- Well-tolerated with most adverse effects resolving shortly after vaccination
- 95% effective
- FDA EUA Review: December 10, 2020



# Pfizer Vaccine Efficacy

- Vaccine efficacy rate of 95% against confirmed COVID-19
- Vaccine efficacy rate over 94% in adults over 65 years of age
- Efficacy consistent across age, gender, race and ethnicity demographics



# Pfizer Vaccine Safety

- Participants followed for a median of 2 months following 2nd dose of vaccine
- Vaccine well tolerated with most solicited adverse events (SAE) resolving shortly after vaccination
  - Most common SAE: injection site reactions, fatigue, headache, muscle pain, chills, joint pain, fever
  - Few Grade 3 SAEs greater than or equal to 2% in frequency (Gr 3 SAE = prevents daily routine activity) – fatigue, headache
- Older adults (over 55 years old) reported fewer and milder SAE following vaccination
- Similar safety profile across age groups, genders, ethnic and racial groups, participants with or without medical comorbidities, participants with or without evidence of prior SARS-CoV-2 infection at enrollment
- US FDA safety milestones achieved for EUA



# Moderna mRNA 1273 Vaccine

- mRNA COVID-19 vaccine
- 2 dose injection, 28 days apart
- Phase 3 clinical trial began July 27, 2020
- Generally well-tolerated with majority of adverse effects mild to moderate
- 94.1% effective
- FDA EUA review: Dec. 17, 2020



# Moderna Vaccine Efficacy

- Vaccine efficacy rate of 94.1% against confirmed COVID-19
- Efficacy consistent across age, race, ethnicity, gender demographics





# Moderna Vaccine Safety

- Solicited adverse events indicate vaccine was well-tolerated
- Majority of adverse events mild or moderate in severity
- Grade 3 SAEs greater than or equal to 2%, generally short-lived (severe = prevents daily routine activity)
  - First dose – injection site pain
  - Second dose – fatigue, myalgia, arthralgia, headache, pain and erythema/redness at injection site
- US FDA safety milestones achieved for EUA



# Dr. Elizabeth Char

Hawai'i State Department of Health Director

---



# Hawaii Vaccine Operations – December 2020

## Allocation:

**45,825** Pfizer 1st doses

**36,000** Moderna 1st doses

**81,825** Allocation in December

## Prioritization:



Healthcare workers  
at risk for exposure



Long-term care staff  
and residents



First responders and essential  
workers



Most hospitals have already  
enrolled



Working with counties on first  
responders and essential  
workers



# Major General Kenneth Hara

- Adjutant General for the State of Hawai'i
- 



# Hilton Raethel

Healthcare Association of Hawai'i President & CEO

---



- HAH and HHEM are working closely with the Hawaii Dept. of Health to vaccinate essential healthcare workers.
- Hospitals are vaccinating their own employees, and in some cases, other healthcare workers in the community.
- There is a federal CVS/Walgreens partnership in place to work with skilled nursing and assisted living facilities to vaccinate workers and the residents in long term care.  
(Moderna vaccine)



# Dr. Kelley Withy

Director, Hawai'i/Pacific Basin Area Health  
Education Center & COVID-19 vaccine clinical  
trial participant

---

